Skip to main content
Clinical Trials/NCT03148977
NCT03148977TerminatedNot Applicable

Evaluating a Point-of-Care, Quantitative Matrix Metalloproteinase Assay as a Predictor of Successful Graft Take in Patients Undergoing Cutaneous Auto Grafting for Acute Burn Injury- A Pilot Study

University of Florida2 sites in 1 country8 target enrollmentStarted: June 9, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
8
Locations
2
Primary Endpoint
Predictability of graft take

Study Overview

Brief Summary

The objective of this study is to determine whether our chemical assay can be used to reliably predict graft take or failure in patients undergoing autologous skin grafting for treatment of acute burn injury.

Detailed Description

This is an observational pilot study of patients treated at UF Health Shands Burn Center adult service. This is a study to determine the predictive value of quantifying concentrations of specific MMPs. Coupling this with a specialized collection sample collection system and a calibrated fluorimetry allows for the rapid assessment of MMP concentrations. This assay has been validated as a predictor of failed wound healing in a published clinical study involving chronic open wounds.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 98 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18 years of age or older
  • Admitted with acute burns injuries (flame, contact or scald) requiring at least one surgical excision and grafting operation will be considered for inclusion
  • Burn injury less than one week old

Exclusion Criteria

  • Electrical, chemical or cold-induced burn injury
  • Total body surface area burn >50 %
  • Pre injury diagnosis of chronic renal insufficiency, liver failure, refusal to accept blood transfusion or withdrawal of care within three days of admission will also be exclusion criteria
  • Patients not expected to survive
  • Patients presenting with re-injury to previously burned and treated areas.
  • Patients who present after receiving burn excision surgery out an outside facility for the current acute injury

Outcomes

Primary Outcomes

Predictability of graft take

Time Frame: 2 years

Determine whether chemical assay can be used to reliably predict graft take or failure in patients undergoing autologous skin grafting for treatment of acute burn injury.

Secondary Outcomes

  • Wound healing(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Evaluating MMPs in Burns | Clinical Trial